Search
Search Results
-
Enhancing prognostic power in multiple myeloma using a plasma cell signature derived from single-cell RNA sequencing
Multiple myeloma (MM) is a heterogenous plasma cell malignancy, for which the established prognostic models exhibit limitations in capturing the full...
-
Immunotherapy for Multiple Myeloma
Multiple myeloma is a clonal disorder of bone marrow plasma cells. Despite the impressive advances in treatment options in the last two decades,...
-
An IL-1β-driven neutrophil–stromal cell axis fosters a BAFF-rich protumor microenvironment in individuals with multiple myeloma
Human bone marrow permanently harbors high numbers of neutrophils, and a tumor-supportive bias of these cells could significantly impact bone...
-
Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database
Autologous stem cell transplant (ASCT) remains an important option for eligible multiple myeloma (MM) patients as part of initial therapy. Using the...
-
Inhibition of USP10 induces myeloma cell apoptosis by promoting cyclin D3 degradation
The cell cycle regulator cyclin D3 (CCND3) is highly expressed in multiple myeloma (MM) and it promotes MM cell proliferation. After a certain phase...
-
Single-cell technologies in multiple myeloma: new insights into disease pathogenesis and translational implications
Multiple myeloma (MM) is a hematological malignancy characterized by clonal proliferation of plasma cells. Although therapeutic advances have been...
-
Long-term outcomes of allogeneic stem cell transplant in multiple myeloma
Allogeneic stem cell transplant (allo SCT) for multiple myeloma (MM) is potentially curative in some, while toxic in many others. We retrospectively...
-
Liquid biopsy by analysis of circulating myeloma cells and cell-free nucleic acids: a novel noninvasive approach of disease evaluation in multiple myeloma
Multiple myeloma (MM) is an incurable hematological cancer with high spatial- and temporal-heterogeneity. Invasive single-point bone marrow sampling...
-
The patients with multiple myeloma were infected with COVID-19 during autologous stem cell transplantation: case report and literature review
This paper introduces two cases of multiple myeloma, COVID-19 infection during autologous stem cell transplantation, the treatment process, and...
-
Proteasomal inhibitors induce myeloma cell pyroptosis via the BAX/GSDME pathway
Proteasomes are overexpressed in multiple myeloma (MM) and proteasomal inhibitors (PIs) have been widely used for the treatment of MM. PIs are...
-
Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation
Autologous stem cell transplantation (autoHCT) is considered standard of care for newly diagnosed multiple myeloma (MM). Although most patients...
-
Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma
Despite being the mainstay of management for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS),...
-
The exploration of B cell maturation antigen expression in plasma cell dyscrasias beyond multiple myeloma
BackgroundB cell maturation antigen (BCMA) targeted immunotherapies have demonstrated remarkable clinical efficacy in multiple myeloma (MM). Here, we...
-
CUDC-101 as a dual-target inhibitor of EGFR and HDAC enhances the anti-myeloma effects of bortezomib by regulating G2/M cell cycle arrest
CUDC-101, an effective and multi-target inhibitor of epidermal growth factor receptor (EGFR), histone deacetylase (HDAC), and human epidermal growth...
-
CAR T therapies in multiple myeloma: unleashing the future
In recent years, the field of cancer treatment has witnessed remarkable breakthroughs that have revolutionized the landscape of care for cancer...
-
-
Chimeric Antigen Receptor T Cell Therapy: A Cutting-Edge Therapy for Multiple Myeloma
Despite advancements in treatment options for multiple myeloma, it still remains an incurable malignancy due to relapse and development of refractory...
-
Cross center single-cell RNA sequencing study of the immune microenvironment in rapid progressing multiple myeloma
Despite advancements in understanding the pathophysiology of Multiple Myeloma (MM), the cause of rapid progressing disease in a subset of patients is...
-
Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma
Chimeric antigen receptor T cells (CAR T) are groundbreaking therapies but may cause significant toxicities including cytokine release syndrome...
-
Multiple myeloma: signaling pathways and targeted therapy
Multiple myeloma (MM) is the second most common hematological malignancy of plasma cells, characterized by osteolytic bone lesions, anemia,...
